Sign In To Continue
You have reached the guest article limit.
Unlock more of the IIPLA newsroom by signing in with SSO or joining as a member.
In a unanimous decision, the U.S. Supreme Court ruled that Amarin Pharma failed to state a claim for active inducement of patent infringement against Hikma Pharmaceuticals. The Court clarified that generic drugmakers using "skinny labels" compliant with FDA regulations and industry practice do not induce infringement…
Share This Article
Ready-to-post copy includes the article link.
Supreme Court Unanimously Rules Against Induced Infringement Claim in Hikma v. Amarin, Clarifying Standards for Generic Drug Labeling In a unanimous decision, the U.S. Supreme Court ruled that Amarin Pharma failed to state a claim for active inducement of patent infringement against Hikma Pharmaceuticals. The Court clarified that generic drugmakers us... Read the full IIPLA article: https://iipla.org/news/supreme-court-unanimously-rules-against-induced-infringement-claim-in-hikma-v-amarin-clarifying-standards-for-generic-drug-labeling